Anti-ST6GAL2 monoclonal antibody

Pre-made anti-ST6GAL2 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to ST6GAL2/ST6GAL2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1829-Ab-1/ GM-Tg-hg-IP1829-Ab-2Anti-Human ST6GAL2 monoclonal antibodyHuman
GM-Tg-rg-IP1829-Ab-1/ GM-Tg-rg-IP1829-Ab-2Anti-Rat ST6GAL2 monoclonal antibodyRat
GM-Tg-mg-IP1829-Ab-1/ GM-Tg-mg-IP1829-Ab-2Anti-Mouse ST6GAL2 monoclonal antibodyMouse
GM-Tg-cynog-IP1829-Ab-1/ GM-Tg-cynog-IP1829-Ab-2Anti-Cynomolgus/ Rhesus macaque ST6GAL2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1829-Ab-1/ GM-Tg-felg-IP1829-Ab-2Anti-Feline ST6GAL2 monoclonal antibodyFeline
GM-Tg-cang-IP1829-Ab-1/ GM-Tg-cang-IP1829-Ab-2Anti-Canine ST6GAL2 monoclonal antibodyCanine
GM-Tg-bovg-IP1829-Ab-1/ GM-Tg-bovg-IP1829-Ab-2Anti-Bovine ST6GAL2 monoclonal antibodyBovine
GM-Tg-equg-IP1829-Ab-1/ GM-Tg-equg-IP1829-Ab-2Anti-Equine ST6GAL2 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1829-Ab-1/ GM-Tg-hg-IP1829-Ab-2; GM-Tg-rg-IP1829-Ab-1/ GM-Tg-rg-IP1829-Ab-2;
GM-Tg-mg-IP1829-Ab-1/ GM-Tg-mg-IP1829-Ab-2; GM-Tg-cynog-IP1829-Ab-1/ GM-Tg-cynog-IP1829-Ab-2;
GM-Tg-felg-IP1829-Ab-1/ GM-Tg-felg-IP1829-Ab-2; GM-Tg-cang-IP1829-Ab-1/ GM-Tg-cang-IP1829-Ab-2;
GM-Tg-bovg-IP1829-Ab-1/ GM-Tg-bovg-IP1829-Ab-2; GM-Tg-equg-IP1829-Ab-1/ GM-Tg-equg-IP1829-Ab-2
Products NameAnti-ST6GAL2 monoclonal antibody
Formatmab
Target NameST6GAL2
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-ST6GAL2 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1829-Ag-1Recombinant multi-species SIAT2/ ST6GAL2/ ST6GalII protein


    Target information

    Target IDGM-IP1829
    Target NameST6GAL2
    Gene ID84620,240119,301155,713552,481315,101098620,493992,100062033
    Gene Symbol and SynonymsC230064G14Rik,mKIAA1877,SIAT2,ST6Gal II,ST6Gal-II,ST6GAL2,ST6GalII
    Uniprot AccessionQ96JF0,Q701R3,A5D7T4
    Uniprot Entry NameSIAT2_HUMAN,SIAT2_RAT,SIAT2_BOVIN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000144057
    Target ClassificationN/A

    The target: ST6GAL2, gene name: ST6GAL2, also named as SIAT2, ST6GalII. This locus encodes a sialyltransferase. The encoded type II transmembrane protein catalyzes the transfer of sialic acid from CMP to an oligosaccharide substrate. Polymorphisms at this locus may be associated with variations in risperidone response in schizophrenic patients. Alternatively spliced transcript variants have been described. [provided by RefSeq, Jan 2012].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.